ADVANCE – IMI project for vaccine benefit/risk assessment

2013 12 02 Written by Vaccines Europe

Vaccines Europe is part of a newly launched five-year EUR 10.7 million IMI (Innovative Medicines Initiative) project aiming to develop a pan-European framework for improved assessment of vaccines benefits and risks. This would represent a landmark step with regards to current practice, where although vaccines undergo rigorous safety testing before regulatory approval, efforts to monitor the coverage, benefits and risks of vaccines post-marketing authorisation remain fragmented across actors and countries. 

The overall goal of the project is to support health professionals, regulatory bodies, public health institutions, vaccine manufacturers, as well as the general public to make informed and evidence-based decisions on the benefits and risks of marketed vaccines. This is intended to help improving the formulation of vaccination strategies as well as improve public confidence in immunisation programmes.

ADVANCE brings together a unique set of key public and private actors, such as ECDC (European Centre for Disease Prevention and Control, EMA (European Medicines Agency), national public health bodies, academic centres of excellence, SMEs as well as major global vaccine manufacturers.

In collaboration with ECDC and other actors in the project, Vaccines Europe will be involved in project activities concerning the assessment of the ‘implementability’ of solutions proposed by other parts of the project through the set-up of expert review panels. This step will be crucial to the development of the framework ‘blueprint’ for integrated benefit/risk assessment in Europe.

 

Related links

IMI press release

ECDC press release

More information on ADVANCE is available here

More information on IMI can be found here